Harvard Apparatus Regenerative Technology, Inc. (HRGN): Entry into a Material Definitive Agreement
Harvard Apparatus Regenerative Technology, Inc. (HRGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the I
How this was made
The 30-second read
Why it matters
The filing discloses a $2.84 million private placement and note conversion by the CEO, providing fresh capital but increasing share count.
Market read
Primary disclosure of a small capital raise for a micro‑cap biotech; limited immediate market impact.
What to watch
CEO's note conversion reduces debt, strengthening balance sheet.
Background
SEC Form 8‑K filing reports Harvard Apparatus Regenerative Technology's entry into a securities purchase agreement and unregistered equity sale.
Ticker impact
Harvard Apparatus Regenerative Technology entered a private placement raising $2.84 million by selling 2.7 M shares at $1.05 each.
Slight downward pressure on the stock due to dilution.
Small raise of $2.8 M in a low‑float micro‑cap is unlikely to move price dramatically, but dilution may cause modest sell‑off.
Market effects
Minimal effect on regenerative‑medicine sector; dilution modestly raises supply of shares.
Limited to US micro‑cap investors.
Low; primarily relevant to niche biotech investors.
Counterpoint
The cash infusion could fund R&D and improve long‑term growth, offsetting dilution concerns.
Key entities
- companyHarvard Apparatus Regenerative Technology, Inc.
Issuer of the private placement.
- personJerry (Junli) He
CEO who purchased shares and converted notes.
